The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making
Michael Wang,Claude Negrier,Frank Driessler,Clifford Goodman,Mark W Skinner
DOI: https://doi.org/10.2147/PPA.S355627
2022-06-10
Patient Preference and Adherence
Abstract:Michael Wang, 1, &ast Claude Negrier, 2, &ast Frank Driessler, 3, &ast Clifford Goodman, 4, &ast Mark W Skinner 5, 6, &ast 1 University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 2 National Reference Center for Haemophilia, Louis Pradel Cardiology Hospital, University of Lyon, Lyon, France; 3 Bayer, Basel, Switzerland; 4 The Lewin Group, Falls Church, VA, USA; 5 Institute for Policy Advancement Ltd, Washington, DC, USA; 6 McMaster University, Hamilton, ON, Canada &astThese authors contributed equally to this work Correspondence: Frank Driessler, Bayer AG, Peter Merian Straße 84, Basel, CH-4052, Switzerland, Tel +41 79 422 32 18, Email Purpose: The anticipated emergence of hemophilia gene therapy will present people with hemophilia (PWH) and treating clinicians with increasingly complex treatment options. It will be critical that PWH and their families be empowered to participate fully in decision-making through transparent communication and the development of targeted educational resources. Methods: The Council of Hemophilia Community (CHC) convened across a series of roundtable meetings to define the patient journey for hemophilia gene therapy, and to develop a question-and-answer style resource to guide discussion between healthcare professionals (HCPs) and their patients. Patient groups were also consulted during the development of this tool. Results: The CHC defined 5 key stages in the hemophilia gene therapy patient journey: pre-gene therapy (information-seeking and decision-making), treatment initiation, short- and long-term post-gene therapy follow-up. PWH will have different questions and concerns at each stage of their journey, which should be discussed with their HCP to aid decision-making. The resulting patient journey infographic and Q&A resource (see Supplementary Materials ) has been developed for HCPs and PWH to provide a novel and practical roadmap of key issues and considerations throughout all stages. Conclusion: These resources support a collaborative, patient-centric, shared decision-making approach to inform treatment decision discussions between HCPs and PWH. The value of such discussions will be influenced by the language adopted; health literacy is a particularly important consideration, and these discussions should be accessible and tailored to PWH. HCPs and PWH can benefit from awareness of the common questions and uncertainties as they progress together along the patient journey. While the contents of this article are specific to hemophilia gene therapy, the concepts developed here could be adapted to aid patients in other disease states. Keywords: hemophilia, patients, HCP guidance, health literacy, disease awareness, treatment landscape Limited literature is available that combines the concepts of the patient journey in hemophilia gene therapy with corresponding life stages. As clinical developments to address the unmet need in hemophilia advance there is also a great need to address the educational and clinical decision-making challenges that will follow market authorization. Herein, we provide a new, interactive, question and answer (Q&A) PDF resource (see Supplementary Materials ) for shared decision-making along the patient journey. Hemophilia is a rare X-linked recessive genetic disease, with an estimated prevalence of 17.1 and 3.8 cases per 100,000 males worldwide for hemophilia A and B, respectively. 1 The current standard of care for severe hemophilia, in countries where it is available, is prophylaxis with factor or non-factor replacement therapy, which aims to prevent bleeds and greatly improves patient outcomes and quality of life. 2 However, people with hemophilia (PWH) remain at increased risk of bleeds (including joint and post-surgical) as well as hematomas (and ensuing synovitis and joint disease) 3 and life-threatening intracerebral hemorrhage. 4,5 As single-gene disorders, hemophilia A and B are promising candidates for gene therapy. Introduction of the missing F8 (hemophilia A) or F9 (hemophilia B) gene aims to deliver a potentially long-term, functionally curative treatment by restoring coagulation factor production to clinically effective levels. Simultaneous goals include ensuring no vector- or transgene-related toxicity and broad patient eligibility across age groups and in patients with inhibitors. 6–8 Gene therapy can therefore offer a new therapeutic option within this treatment landscape, to fit the needs of each individual. Different gene therapy products are likely to -Abstract Truncated-
medicine, general & internal